News - Page 121 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

Post published:February 16, 2022
Post category:Press Release

Read more about the article Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism

Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism

Post published:February 16, 2022
Post category:Press Release

Read more about the article Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Post published:February 16, 2022
Post category:Press Release

Read more about the article atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine

atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine

Post published:February 16, 2022
Post category:Press Release

Read more about the article Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program

Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program

Post published:February 16, 2022
Post category:Press Release

Read more about the article Lobe Sciences Ltd. Strengthens Its Balance Sheet

Lobe Sciences Ltd. Strengthens Its Balance Sheet

Post published:February 16, 2022
Post category:Press Release

Read more about the article BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model

Post published:February 15, 2022
Post category:Press Release

Read more about the article Psyched Wellness Announces Key Findings from the 90-Day Oral Toxicity Study on AME-1

Psyched Wellness Announces Key Findings from the 90-Day Oral Toxicity Study on AME-1

Post published:February 15, 2022
Post category:Press Release

Read more about the article Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

Post published:February 15, 2022
Post category:Press Release

Read more about the article Field Trip Health Ltd. Reports Third Fiscal Quarter 2022 Financial Results and Provides Business Update

Field Trip Health Ltd. Reports Third Fiscal Quarter 2022 Financial Results and Provides Business Update

Post published:February 15, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.